Search Results

You are looking at 201 - 210 of 858 items for :

  • Refine by Access: All x
Clear All
Full access

Oncology Research Program

enzalutamide, a potent androgen receptor (AR) antagonist, in the treatment of patients with mantle cell lymphoma (MCL) that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Preclinical studies

Full access

Oncology Research Program

enzalutamide, a potent androgen receptor (AR) antagonist, in the treatment of patients with mantle cell lymphoma (MCL) that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Preclinical studies

Full access

Oncology Research Program

enzalutamide, a potent androgen receptor (AR) antagonist, in the treatment of patients with mantle cell lymphoma (MCL) that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Preclinical studies

Full access

Multiple Myeloma

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Edward A. Faber Jr., Cristina Gasparetto, Carol Ann Huff, Adetola Kassim, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Guido Tricot, Donna M. Weber, Joachim Yahalom, and Furhan Yunus

and more effective treatment options. 2 , 3 MM is typically sensitive to a variety of cytotoxic drugs, both as initial treatment and as treatment of relapsed disease. Unfortunately, responses are transient, and MM is not considered curable with

Full access

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018

Shaji K. Kumar, Natalie S. Callander, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jorge Castillo, Jason C. Chandler, Caitlin Costello, Matthew Faiman, Henry C. Fung, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Yubin Kang, Adetola Kassim, Michaela Liedtke, Ehsan Malek, Thomas Martin, Vishala T. Neppalli, James Omel, Noopur Raje, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Donna Weber, Joachim Yahalom, Rashmi Kumar, and Dorothy A. Shead

available. These NCCN Guidelines Insights focus on updates to the 2018 version of the NCCN Guidelines for MM, including those regarding therapy options for both newly diagnosed and relapsed/refractory (R/R) MM. There are several classes of agents used

Full access

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018

Gregory P. Kalemkerian, Billy W. Loo Jr, Wallace Akerley, Albert Attia, Michael Bassetti, Yanis Boumber, Roy Decker, M. Chris Dobelbower, Afshin Dowlati, Robert J. Downey, Charles Florsheim, Apar Kishor P. Ganti, John C. Grecula, Matthew A. Gubens, Christine L. Hann, James A. Hayman, Rebecca Suk Heist, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar A. Moran, Daniel Morgensztern, Saraswati Pokharel, David C. Portnoy, Deborah Rhodes, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Charles C. Williams Jr, Karin G. Hoffmann, and Miranda Hughes

(Subsequent) Systemic Therapy Although SCLC is very responsive to initial treatment, most patients experience relapse with relatively resistant disease. 26 – 28 Randomized phase III trials have demonstrated the benefit of single-agent topotecan orally or

Full access

Optimizing BTK Inhibition in Waldenström Macroglobulinemia

Shayna Sarosiek and Jorge J. Castillo

immunosuppression associated with chemoimmunotherapy, BTK inhibitor therapy should be considered in the frontline setting or in patients with relapsed disease who have not yet been exposed to BTK inhibitors. Figure 1 shows a proposed genomics-driven treatment

Full access

CLO24-060: Organomegalies as a Predictive Indicator of Leukemia Cutis in the Patients With Acute Myeloid Leukemia

Chalothorn Wannaphut, Chanakarn Kanitthamniyom, Penvadee Pattanaprichakul, Smith Kungwankiatichai, and Weerapat Owattanapanich

and relapse-free survival were assessed. Pathological tissues underwent re-evaluation to validate LC diagnoses. The study included 159 patients in a 2:1 ratio (106 non-LC and 53 LC). The LC group had a mean age of 54.3 ± 15.5 years and a female

Full access

YIA23-003: CD19-CAR T Cells Develop Exhaustion Epigenetic Programs During a Clinical Response

Caitlin Zebley, Charmaine C Brown, Tian Mi, Yiping Fan, Shanta Alli, Shannon Boi, Giovanni Galletti, Enrico Lugli, Deanna Langfitt, Jean-Yves Metais, Timothy Lockey, Michael Meagher, Brandon Triplett, Aimee Talleur, Stephen Gottschalk, and Ben Youngblood

to mount an in vivo recall response after relapse of antigen-positive disease or recovery of endogenous B cells. Conclusions: These observations support the conclusion that CD19-CAR T cells acquire stable epigenetic exhaustion programs that limit

Full access

Chronic Myelogenous Leukemia, Version 1.2015

Susan O’Brien, Jerald P. Radich, Camille N. Abboud, Mojtaba Akhtari, Jessica K. Altman, Ellin Berman, Peter Curtin, Daniel J. DeAngelo, Michael Deininger, Steven Devine, Amir T. Fathi, Jason Gotlib, Madan Jagasia, Patricia Kropf, Joseph O. Moore, Arnel Pallera, Vishnu VB. Reddy, Neil P. Shah, B. Douglas Smith, David S. Snyder, Meir Wetzler, Kristina Gregory, and Hema Sundar

(hyper-CVAD) has been shown to be effective for the treatment of patients with lymphoid BP-CML. 93 , 94 In a study of 34 patients with lymphoid BP-CML or relapsed Ph+ ALL, the addition of dasatinib to hyper-CVAD resulted in an overall response rate of 91